Tests ADN : en faillite, 23andMe vend sa banque de données à un groupe pharmaceutique | Les Echos


AI Summary Hide AI Generated Summary

Key Details

23andMe, a bankrupt genetic testing company, has sold its extensive DNA database to Regeneron Pharmaceuticals for $256 million. This database reportedly contains the genetic information of approximately 15 million individuals.

Concerns Raised

The sale raises concerns regarding data privacy and the commercialization of personal genetic information. The transfer of such sensitive data from one entity to another highlights the ethical and legal complexities surrounding the use of personal genetic data.

Impact

This transaction marks a significant event in the industry, underscoring both the market value of large genetic databases and the potential risks associated with the commercialization of personal genetic data.

Sign in to unlock more AI features Sign in with Google

Voir ses données personnelles (adresse, numéro de téléphone, etc.) passer de main en main est déjà inquiétant, alors que dire lorsqu'il s'agit de son profil ADN ? Lundi, la société de tests génétiques en faillite 23andMe a accepté de vendre sa banque de données, qui contient des échantillons d'ADN d'environ 15 millions de personnes, au développeur de médicaments Regeneron Pharmaceuticals, pour 256 millions de dollars.

Was this article displayed correctly? Not happy with what you see?

Tabs Reminder: Tabs piling up in your browser? Set a reminder for them, close them and get notified at the right time.

Try our Chrome extension today!


Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more

Facebook

Save articles to reading lists
and access them on any device


Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more

Facebook

Save articles to reading lists
and access them on any device